Viana, V.G. et al. 2026. ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES. Seven Editora. (Jan. 2026), 43–55.